Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Position Increased by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 74.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 731,900 shares of the biopharmaceutical company’s stock after purchasing an additional 312,000 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.61% of Catalyst Pharmaceuticals worth $15,421,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CPRX. abrdn plc purchased a new position in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $10,115,000. Raymond James Financial Inc. bought a new stake in Catalyst Pharmaceuticals in the fourth quarter worth approximately $6,887,000. Jane Street Group LLC grew its position in Catalyst Pharmaceuticals by 245.4% in the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after acquiring an additional 285,564 shares in the last quarter. Walleye Capital LLC bought a new stake in Catalyst Pharmaceuticals in the third quarter worth approximately $4,936,000. Finally, Pacer Advisors Inc. grew its position in Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after acquiring an additional 151,495 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Bank of America reissued a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Stephens restated an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $32.50.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX opened at $20.87 on Friday. The stock has a market cap of $2.53 billion, a P/E ratio of 17.69, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $24.64. The company has a fifty day moving average price of $22.28 and a 200 day moving average price of $21.52.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.